- Posted January 27, 2014 by
Manhattan Beach, California
This iReport is part of an assignment:
Living with a rare disease?
- Pancreatic Cancer Action Network, Rising Tide Foundation for Clinical Research, and Gateway for Cancer Research Award More Than $1.2 Million in Grants
- Pancreatic to Surpass Breast and Colon Cancer to Become the Second Deadliest Cause of Cancer Death Around 2020
- New Chemotherapy Combination Extends Survival For Metastatic Pancreatic Cancer By Nearly Two Months
- Nearly $ 5 Million in Research Awarded for Innovative Pancreatic Cancer Research
- National Cancer Institute Releases Report Outlining Scientific Framework to Address Pancreatic Cancer
Clinical Trial Participation Today May Lead to Future Breakthroughs in Pancreatic Cancer
January marks the annual observance of National Pancreatic Cancer Clinical Trials Awareness Month. The five year survival rate of pancreatic cancer is just six percent. In the effort to highlight the urgent need to improve the survival rate for this disease, the Pancreatic Cancer Action Network is educating the public about clinical trials and the critical role they play in making scientific progress.
In particular for pancreatic cancer, with few effective treatment options for patients, clinical trials are an extremely important part of the research process as scientists seek new, better treatments that will ultimately increase survival. Studies have determined that both a lack of awareness and low prioritization of clinical trials by physicians and patients facing cancer contribute to the low enrollment rates.
“Clinical trials are the way to make progress towards better treatments – participation today will shape the treatment landscape for the future,” says Julie Fleshman, president and CEO of the Pancreatic Cancer Action Network. “In addition to being treated with new and innovative therapies, patients will be making a contribution to science by helping researchers learn more about the disease and help improve cancer care.”
In 2013, nearly 45,000 Americans were diagnosed with pancreatic cancer and more than 38,000 died from the disease. A recent analysis reveals that pancreatic cancer is projected to move from the fourth to the second leading cause of cancer death in the United States by the year 2020. Now more than ever, we need to change the course of pancreatic cancer.
“It is also essential for patients to know, that in all pancreatic cancer trials, patients always receive either the best standard treatment or the treatment being evaluated in the trial,” adds Fleshman. “Thanks to clinical trial research and participation, significant advancements in the field of pancreatic cancer have been made. However, much still lies ahead.”
To bring attention to the need for clinical trials and to increase enrollment, the organization’s Patient and Liaison Services (PALS) program educates patients and caregivers about their options and the value of clinical trials. The program also conducts personalized searches using the organization’s comprehensive, proprietary clinical trials database to determine potential eligibility. This database is the nation’s leading resource for pancreatic cancer clinical trials.
To learn more about the Pancreatic Cancer Action Network, the PALS program and clinical trials, visit www.pancan.org/pals.
About the Pancreatic Cancer Action Network
The Pancreatic Cancer Action Network is the national organization creating hope in a comprehensive way through research, patient support, community outreach and advocacy for a cure. The organization is leading the way to increase the survival rate for people diagnosed with this devastating disease through a bold initiative — The Vision of Progress: Double the Pancreatic Cancer Survival Rate by 2020. Together, we can know, fight and end pancreatic cancer by intensifying our efforts to heighten awareness, raise funds for comprehensive private research, and advocate for dedicated federal research to advance early diagnostics, better treatments and increase chances of survival.